SIGA Technologies stock reports USD 41.0 million Q2 revenue

Published on 10/07/2026 at 06:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

SIGA Technologies stock was trading at USD 3.35 on October 2, 2026, while Q2 revenue fell to USD 41.0 million. Management is pursuing a successor government contract.

SIGA, US8269171067, Illustration mit AI erstellt.

SIGA Technologies stock was trading at USD 3.35 on Nasdaq on October 2, 2026, while the company navigates weaker year-over-year results and a transition in government procurement. The latest Q2 update showed revenue of USD 41.0 million and diluted EPS of USD 0.17.

Q2 revenue fell 49.4 percent

According to The Globe and Mail on August 6, 2026, SIGA reported USD 41.0 million of total revenue for the quarter ended June 30, 2026, compared with USD 81.1 million in Q2 2025. The 49.4 percent decline reflects the timing of product deliveries, making the quarterly comparison particularly important for a company dependent on government procurement cycles.

Profitability also moved lower. Diluted EPS was USD 0.17 in Q2 2026 versus USD 0.49 a year earlier, while net income declined to USD 12.5 million from USD 35.5 million.

Government contract is the key variable

The same The Globe and Mail report said SIGA completed its final product obligations under the previous 19C contract and is negotiating a successor multiyear agreement with the U.S. government. The Q2 delivery included USD 24 million of intravenous TPOXX for the Strategic National Stockpile and USD 13 million of international sales.

That concentration explains why the first-half figures were softer even though Q2 remained profitable. First-half revenue was USD 47.2 million, compared with USD 88.2 million in the first half of 2025, and first-half diluted EPS was USD 0.13 versus USD 0.49.

Cash supports the transition

SIGA entered the procurement transition with USD 117.6 million of cash as of June 30, 2026, and no debt, according to The Globe and Mail. Management is also targeting an FDA submission for a post-exposure prophylaxis program in the first half of 2027, while pediatric program results are expected by year-end 2026.

For investors, the central issue is the timing of the next large procurement award. TPOXX demand remains tied to public-sector stockpiling, so contract timing can produce large changes between individual quarters.

SIGA stock stays below its yearly high

SIGA stock was trading at USD 3.35 on Nasdaq on October 2, 2026. MarketBeat listed a 52-week range of USD 2.83 to USD 9.25 and a market capitalization of USD 240.7 million on that date.